Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists for bradykinin mediated diseases. Harnessing established science, the company aims to deliver oral bradykinin B2 receptor antagonists to help address unmet needs and improve standard of care.

Our legacy, scientific expertise, and values drive our passion as we aspire to provide choice to people living with bradykinin-mediated diseases.

For more information, visit https://pharvaris.com/